Key result
TRPV4 antagonist GSK2193874 increases tail blood flow across ambient temperatures in mice.
Why the study?
Previous studies showed TRPV4 can act as a local vasodilator in blood vessels, but whether TRPV4 activity affects tail vascular tone and thermoregulation in mice was unclear.
Does intraperitoneal administration of the TRPV4 antagonist GSK2193874 affect tail blood flow and thermoregulation in lightly sedated CD1 mice?
Does intraperitoneal administration of the TRPV4 antagonist GSK2193874 affect tail blood flow and thermoregulation in lightly sedated CD1 mice?
p-value: p=≤0.05
Systemic administration of the TRPV4 antagonist GSK2193874 unexpectedly increases tail blood flow in mice, suggesting a central mechanism of action rather than direct peripheral vasodilation.
No immediate clinical implications; leaves open central TRPV4 effects on thermoregulation for future study.
In humans the skin is a primary thermoregulatory organ, with vasodilation leading to rapid body cooling, whereas in Rodentia the tail performs an analogous function. Many thermodetection mechanisms are likely to be involved including transient receptor potential vanilloid-type 4 (TRPV4), a widely distributed ion channel with both mechanical and thermosensitive properties. Previous studies have shown that TRPV4 can act as a vasodilator by local action in blood vessels, and in this study, we investigated whether TRPV4 activity effects mus muscularis tail vascular tone and thermoregulation. We measured tail blood flow by pressure plethysmography in lightly sedated mus muscularis (CD1 strain) at a range of ambient temperatures, with and without intraperitoneal administration of the blood brain barrier crossing TRPV4 antagonist GSK2193874. We also measured heart rate and blood pressure with and without GSK2193874. As expected for a thermoregulatory organ, we found that tail blood flow increased with temperature. However, unexpectedly we found that the TRPV4 antagonist GSK2193874 increased tail blood flow at all temperatures, and we observed changes in heart rate variability. Since TRPV4 activation stimulates the relaxation of peripheral resistance arteries (vasodilation) that would increase tail blood flow, these data suggest that increases in tail blood flow resulting from the TRPV4 antagonist may arise from a site other than the blood vessels themselves, perhaps in central cardiovascular control centres such as the hypothalamus.
No takes yet. Share an insight, caveat, or question.
O’Brien et al. (2021) studied Thermoregulation (n=14). GSK2193874 vs. Control (without GSK2193874) was evaluated on Tail blood flow measured by volume pressure plethysmography (p=≤0.05). Systemic administration of the TRPV4 antagonist GSK2193874 significantly increased tail blood flow in mice across a range of ambient temperatures (p≤0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: